Choice of Oral & Poster Presentations
Sagar Lonial, Niels W.C.J. van de Donk, Rakesh Popat, Jeffrey A. Zonder, et al.
Conclusions: IBER + DEX showed favorable efficacy and safety in heavily pretreated pts with RRMM who failed multiple prior therapies. This study is ongoing, including combinations of IBER with DARA or BORT. Clinical trial information: NCT02773030
|Efficacy||IBER dose 0.3–1.2 mg + DEX
(N = 51 evaluable)
|Very good partial response||1|
|Partial response (PR)||15|
|Minimal response (MR)||10|
|Stable disease (SD)||19|
|Overall response (≥ PR)||16 (31%)|
|Clinical benefit (≥ MR)||26 (51%)|
|Disease control (≥ SD)||45 (88%)|
Francesca Gay, Chiara Cerrato, Maria Teresa Petrucci, Renato Zambello, et al.
Conclusions: KRd-ASCT-KRd and KRd12 were equally effective in inducing high-quality responses, with about 50% of high-risk pts achieving MRD negativity. In high-risk pts ASCT reduced the risk of early relapse. Clinical trial information: NCT02203643
Sagar Lonial, Susanna J. Jacobus, Matthias Weiss, Shaji Kumar, et al.
Conclusions: Overall, this trial represents the largest randomized trial in SMM to date. In conjunction with the Spanish data, this trial may support a change in clinical practice. Clinical trial information: NCT01169337
|Phase 2 PFS|
|Phase 3 PFS||Len||Obs|
Paul G. Richardson, Michel Attal, S. Vincent Rajkumar, Jesus San Miguel, et al.
A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
Conclusions: IsaPd significantly improved PFS and ORR vs Pd, with a manageable safety profile. IsaPd is an important new treatment option for the management of RRMM. Clinical trial information: NCT02990338
Conclusions: D-Rd pts received less R vs Rd group regardless of age. Efficacy of D-Rd in <75 and ≥75 y pts was consistent with the ITT population, and D-Rd demonstrated acceptable tolerability regardless of age. Together with the phase 3 ALCYONE study, these studies confirm clinical benefit of daratumumab plus standard-of-care in transplant-ineligible NDMM pts ≥75 y of age. Clinical trial information: NCT02252172
|HR (95% CI)||0.50 (0.35-0.71)||0.63 (0.44-0.92)|
|30-mo PFS, %||75||58||66||52|
|MRD-negative rate, % (10-5)||28||7||19||8|
Jonathan L. Kaufman, Meletios A. Dimopoulos, Merav Leiba, James Morton, et al.
Conclusions: D-Rd demonstrates significant efficacy in high-risk RRMM. Among high-risk pts, MRD negativity was only achieved with D-Rd. Clinical trial information: NCT02076009
(n = 204)
(n = 178)
(n = 48)
(n = 55)
|MRD neg, %a||32.9||8.2||<0.0001||28.6||0||<0.0001|
|≥MRD neg (≥6 mo), %a||17.9||1.1||<0.0001||12.2||0||0.0082|
|≥MRD neg (≥12 mo), %a||14.0||0.5||<0.0001||10.2||0||0.0188|
Claire N. Harrison, Nicolaas Schaap, Alessandro M Vannucchi, Jean-Jacques Kiladjian, et al.
Conclusions: FEDR provided clinically meaningful reductions in splenomegaly and symptom burden in pts with MF who met more stringent criteria for R/R or intolerance to RUX. Clinical trial information: NCT01523171
|Prior Analysis||Current Analysis|
|Resistance||RUX Tx ≥ 14 d with no response or stable disease per investigator, disease progression, or loss of response||Relapsed: RUX Tx ≥ 3 mo with regrowth, defined as < 10% SVR or < 30% decrease in spleen size from BL, following an initial response
Refractory: RUX Tx ≥ 3 mo with < 10% SVR or < 30% decrease in spleen size from BL
|Intolerance||RUX Tx ≥ 14 d before discontinuing Tx due to unacceptable toxicity||RUX Tx ≥ 28 d complicated by development of RBC transfusion requirement (≥ 2 units/mo for 2 mo); or grade ≥ 3 thrombocytopenia, anemia, hematoma/hemorrhage while on RUX|